Elantas Beck Fair Value
Elantas Beck (ELANTAS) average fair value is ₹4061.41 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹9147.5 (-55.6%), fair value range ₹1260.0–₹11374.93. See ELANTAS P/B ratio history to compare market price against book value per share.
Fair Value Analysis Export
ELANTAS Fair Value vs Current Price — Valuation Summary
ELANTAS average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Also explore Elantas Beck share price performance to track price trends across different timeframes.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
ELANTAS Fair Value Analysis — Data Sources & Coverage
Elantas Beck financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit Elantas Beck stock price NSE.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
ELANTAS vs Chemicals Sector Peers — P/E, P/B & Market Cap
Elantas Beck P/E ratio, P/B ratio and market capitalisation vs Chemicals sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Polychem | POLYCHEM | 2.51 | 1.71 | ₹82 |
| HP Adhesives | HPAL | 48.29 | 1.8 | ₹338 |
| Blue Pearl Agriventures | BPAGRI | 2450.0 | 24.2 | ₹1,476 |
| Omkar Pharmachem | OMKARPH | 337.5 | 2.86 | ₹27 |
| Citurgia Biochemicals | CITURGIA | -2027.0 | -136.13 | ₹1,365 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.